Pimasertib (AS-703026)

Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. Phase 2.

Price Stock Quantity  
In DMSO USD 160 In stock
USD 90 In stock
USD 150 In stock
USD 270 In stock
USD 450 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pimasertib (AS-703026) Chemical Structure

Pimasertib (AS-703026) Chemical Structure
Molecular Weight: 431.20

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Pimasertib (AS-703026) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area

Product Description

Biological Activity

Description Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. Phase 2.
Targets MEK1/2 (MM cell line) [1]
(Cell-free assay)
IC50 5 nM-2 μM
In vitro AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor that binds to the distinctive MEK allosteric site and therefore exhibits exquisite kinase selectivity. AS703026 inhibits growth and survival of human multiple myeloma (MM) cells, including U266 and INA-6, with IC50 of 5 nM and 11 nM, respectively. Such an inhibitory effect by AS703026 is mediated by G0-G1 cell cycle arrest and is accompanied by reduced expresson of the MAF oncogene. AS703026 further induces apoptosis via caspase-3 and PARP cleavage in MM cells, both in the presence or absence of bone marrow stromal cells (BMSCs). [1] AS703026 may be an effective therapy in colorectal cancer caused by K-Ras mutation. AS703026 (10 μM) effectively inhibits the ERK pathway, proliferation, and transformation in human DLD-1 colorectal cancer cells what carry a mutant allele of K-Ras (D-MUT). [2]
In vivo AS703026 (15 and 30 mg/kg) significantly inhibits tumor growth in a human plasmacytoma xenograft model of H929 MM cells. This can be correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels. [1] AS703026 (10 mg/kg) inhibits tumor growth, and markedly decreases p-ERK level in a xenograft mouse model of human K-Ras mutated (D-MUT) colorectal tumor. [2]
Features A novel, highly selective and potent allosteric inhibitor of MEK1/2.

Protocol(Only for Reference)

Kinase Assay: [3]

MEK1 enzyme assays AS703026 is dissolved in 2.5% DMSO. Activated diphosphorylated MEK (pp-MEK) assays contained 40 μM 33P-γATP (AppKm 8.5 μM), 0.5 nM human-activated MEK1 or MEK2, 1 μM kinase-dead ERK2 (AppKm 0.73 μM). All assays are done in buffer containing 20 mM HEPES (pH 7.2), 5 mM 2-mercaptoethanol, 0.15 mg/mL BSA, and 10 mM MgCl2. The final concentration of 33P- ATP is 0.02 μCi/μL for all the assays. pp-MEK kinase reactions are stopped after 40 min by transferring 30 μL of reaction mixture to Durapore 0.45-μm filters plates containing 12.5% TCA. Filters are dried and read with liquid scintilant on a TopCount. Concentration response data are analyzed for IC50. 0.2 nM recombinant human MEK1 or MEK2 is preincubated with vehicle or with AS703026 for 40 minutes in reaction buffer to determine IC50 of initially unphosphorylated MEK (u-MEK). Phosphorylation/activation is initiated by the addition of a final concentration of 20 nM final B-RafV600E and 30 μM final ATP for 10 min. B-Raf activity is then quenched by addition of the B-Raf inhibitor SB590885 (final concentration 100 nM), and MEK kinase activity is assayed by the addition of 1 μM KD-ERK2 and 0.02 μCi/μL 33P-ATP in reaction buffer. The kinase reactions are stopped after 90 min by transferring 30μL of reaction mixture to a Durapore filter plate, and read as above.

Cell Assay: [1]

Cell lines U266 and INA-6 cells
Concentrations 2 nM - 20 μM (stock: 10 mM in DMSO)
Incubation Time 48 hours
Method Cytotoxicity assays for AS703026 are assessed by measuring both [3H]thymidine incorporation and MTT dye absorbance. Cells (1 × 104 per well) are cultured in 96-well plates for 3 days. For the [3H]thymidine incorporation assay, cells are pulsed with 18.5 kBq/well [3H]thymidine for 6 hours, harvested onto glass fibre filters, and counted in a β-scintillation counter. Cell cycle analysis is assessed by propidium iodide (PI) staining using flow cytometry. AS703026-induced apoptosis is determined by annexin-V/PI staining and flow cytometric data analysis.

Animal Study: [1]

Animal Models H929 MM xenografts are established in CB17 (SCID) mice
Formulation 10 mg/mL, dissolved in 0.5% carboxymethylcellulose / 0.25% Tween20
Dosages 15 or 30 mg/kg
Administration Oral gavage twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Kim K, et al. Br J Haematol, 2010, 149(4), 537-549.

[2] Yoon J, et al. Cancer Res, 2011, 71(2), 445-453

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-08-29)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01992874 Completed Neoplasms EMD Serono November 2013 Phase 1
NCT01985191 Recruiting Neoplasm Malignant Sanofi|Merck KGaA November 2013 Phase 1
NCT01936363 Active, not recruiting Ovarian Cancer EMD Serono|Sanofi September 2013 Phase 2
NCT01693068 Active, not recruiting N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma EMD Serono December 2012 Phase 2
NCT01713036 Completed Locally Advanced or Metastatic Solid Tumors Merck KGaA|Merck Serono S.A., Switzerland November 2012 Phase 1

view more

Chemical Information

Download Pimasertib (AS-703026) SDF
Molecular Weight (MW) 431.20
Formula

C15H15FIN3O3

CAS No. 1236699-92-5
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms MSC1936369B, SAR 245509
Solubility (25°C) * In vitro DMSO 86 mg/mL (199.44 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide

Customer Product Validation (3)


Click to enlarge
Rating
Source FASEB J 2014 10.1096/fj.13-247924. Pimasertib (AS-703026) purchased from Selleck
Method Western blot
Cell Lines MKN-45 cells
Concentrations 0.5 uM
Incubation Time 24, 48 h
Results Using biochemical inhibitors of the above signal transducers, it investigated whether HSP27 induction associated with MET inhibition relied on MEK/ERK and/or PI3K/AKT pathways. HSP27 was induced by 2 other structurally unrelated MEK inhibitors: PD98059 or AS703026.

Click to enlarge
Rating
Source Endocrinology 2013 154(9), 3219-27. Pimasertib (AS-703026) purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations 0-10 uM
Incubation Time 30 min
Results Inhibition of ERK activation by AS703026 , a novel MAPK kinase (MEK) inhibitor, disrupted the ability of E2 and GH+E2 to stimulate cell proliferation.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Pimasertib (AS-703026) purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations 0-10 μM
Incubation Time 3 h
Results AS703026 decreased protein expression levels of p-ERK1/2, but had no effect on ERK1/2.

Product Use Citation (4)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • PD184352 (CI-1040)

    PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

    Features:First MEK inhibitor to begin clinical development.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

Recently Viewed Items

Tags: buy Pimasertib (AS-703026) | Pimasertib (AS-703026) supplier | purchase Pimasertib (AS-703026) | Pimasertib (AS-703026) cost | Pimasertib (AS-703026) manufacturer | order Pimasertib (AS-703026) | Pimasertib (AS-703026) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us